Pure Global AI
NCT06281106Not yet recruiting

TYK2 Inhibition in Paradoxical Psoriasis

Tyrosine Kinase 2 (TYK2) Inhibition in Paradoxical Psoriasis A Randomized, Double-blind, Placebo-controlled Multi-center Study Evaluating the Effect of Deucravacitinib on Severity of Psoriasis in Patients With Paradoxical Psoriasis
Prof Curdin ConradPhase 2/3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Psoriasis
Drug/Device/Intervention
Deucravacitinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Prof Curdin Conrad
Funder
Centre Hospitalier Universitaire Vaudois
Location
Lausanne, Switzerland
Timeline & enrollment
Phase
Phase 2/3
Start date
Apr 01, 2024
End date
Aug 01, 2025
Enrollment
26 participants
Primary outcome

Paradoxical Psoriasis Investigator Global Assessment

Summary

Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor
 agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or
 the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped
 and so far, no specific treatment for paradoxical psoriasis exists.
 
 This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a
 tablet taken by mouth once a day is superior compared to taking a placebo in treating
 paradoxical psoriasis.

ICD-10 classifications
PsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasisPsoriasis vulgaris
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06281106
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06281106 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Prof Curdin Conrad and is currently Not yet recruiting. The study focuses on Psoriasis. Target enrollment is 26 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.